Trends in United States prostate cancer incidence rates by age and stage, 1995-2012

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 2, 2016, Pages 259-263

  Hoffman, Richard M ^a,b   Meisner, Angela L W ^c   Arap, Wadih ^c,d   Barry, Marc ^c,d   Shah, Satyan K ^c,d   Zeliadt, Steven B ^e   Wiggins, Charles L ^c,d  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e Puget Sound VA Medical System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; CANCER REGISTRY; CANCER STAGING; EARLY CANCER DIAGNOSIS; HISTORY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; UNITED STATES;

AGE FACTORS; AGED; EARLY DETECTION OF CANCER; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 84957794710     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0723     Document Type: Review

References (35)

1. American Urological Association. Early detection of prostate cancer and use of transrectal ultrasound. In: American Urological Association 1992 Policy Statement Book. Baltimore, MD: American Urological Association; 1992.
2. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993;43: 42-6.
3. Howlader , Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: NCI; 2015.
4. von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American Cancer Society guideline for the early detection of prostate cancer: update 1997. CA Cancer J Clin 1997;47:261-4.
5. American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology. 2000;14:267-72.
6. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:185-91.
7. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
8. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. NEngl J Med 2009;360:1310-9.
9. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70-98.
10. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190:419-26.
11. Goldberg P. USPSTF to downgrade PSA screening from "I" to "D" - as in "don't do it". Cancer Lett. 2011;37:(1-4 pp). Available from: http://www.cancerletter.com/articles/20111006.
12. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157: 120-34.
13. Aslani A, Minnillo BJ, Johnson B, Cherullo EE, Ponsky LE, Abouassaly R. The impact of recent screening recommendations on prostate cancer screening in a large health care system. J Urol 2014;191: 1737-42.
14. Cohn JA, Wang CE, Lakeman JC, Silverstein JC, Brendler CB, Novakovic KR, et al. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urol Oncol 2014;32:41.
15. Goodwin JS, Tan A, Jaramillo E, Kuo YF. Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials. J Natl Cancer Inst 2013;105:743-5.
16. Howard DH. Declines in prostate cancer incidence after changes in screening recommendations. Arch Int Med 2012;172:1267-8.
17. Howard DH, Tangka FK, Guy GP, Ekwueme DU, Lipscomb J. Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation. Health Aff. 2013;32: 596-602.
18. Pollack CE, Noronha G, Green GE, Bhavsar NA, Carter HB. Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. Arch Intern Med 2012; 172:668-70.
19. Ross JS, Wang R, Long JB, Gross CP, Ma X. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med 2012;172:1601-3.
20. Scosyrev E, Wu G, Golijanin D, Messing E. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU Int 2012;110:1485-90.
21. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101:1325-9.
22. Tasian GE, Cooperberg MR, Potter MB, Cowan JE, Greene KL, Carroll PR, et al. PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostatic Dis 2012;15:189-94.
23. Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007;167: 2497-502.
24. Li J, Djenaba JA, Soman A, Rim SH, Master VA. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001- 2007. Prostate Cancer 2012;2012:691380.
25. Surveillance Research Program, National Cancer Institute. SEER-Stat Software (seer.cancer.gov/seerstat) version 7.1.0.
26. Joinpoint Regression Program. 3.5.2. October 2011; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.
27. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19: 335-51.
28. Bhindi B, Mamdani M, Kulkarni GS, Finelli A, Hamilton RJ, Trachtenberg J, et al. Impact of the U.S. Preventive Services Task Force Recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J Urol 2015;193:1519-24.
29. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol 2014;11:317-23.
30. Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostatespecific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004;38:732-44.
31. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003;289:1414-20.
32. Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 2012;307:1692-4.
33. Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416-23.
34. Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, et al. Prostate cancer trends 1973-1995. SEER Program, National Cancer Institute, NIH Pub. No. 99-4543 Bethesda, MD, 1999.
35. Barocas DA, Mallin K, Graves AJ, Penson DF, Palis B, Winchester DP, et al. The effect of the United States Preventive Services Task Force grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the US. J Urol 2015;194: 1587-93.